Investor Profile: Third Rock Ventures — Thesis, Cheque Size & How to Apply

Founders researching Third Rock Ventures funding should understand the firm's unusual model first: Third Rock does not just back life-science start-ups, it launches them. Operating under the mantra "Discover. Launch. Build. Transform.", the Boston and San Francisco firm identifies promising science, assembles world-class teams and builds companies from the ground up — often incubating them in its own offices. In 19 years it has built 73 portfolio companies and helped deliver 27 marketed products.

Thesis and focus areas

Third Rock's thesis is company creation around breakthrough science with the potential to make a difference in patients' lives. Rather than waiting for start-ups to come to it, the team collaborates with entrepreneurs and deep academic and industry networks to establish the roadmap and building blocks for rapidly growing life-sciences companies, engaging hands-on across strategy, operations, people and culture. Focus areas span oncology, immunology, neuroscience, rare diseases, gene and cell therapy, drug-discovery platforms and novel therapeutic modalities.

Cheque size and stage

Third Rock invests at the earliest stages — seed and Series A — leads rounds, and holds a significant stake as companies grow. The firm has raised $3.8 billion since its 2007 founding, including a $1.1 billion fund closed in 2022. Third-party trackers cite typical investments of $10 million to $100 million, reflecting a model built for capital-intensive therapeutic development rather than lean software bets.

Notable portfolio

Recent Third Rock companies illustrate the model: Revolution Medicines, whose RASONQUE (daraxonrasib) became the first broad RAS-targeted medicine approved for metastatic pancreatic cancer; Agios Pharmaceuticals (mitapivat, marketed for thalassemia and PK deficiency); Decibel Therapeutics, whose Otarmeni gene therapy for genetic hearing loss arrived via its acquisition by Regeneron; Taris Bio, whose INLEXZO bladder-cancer therapy came through Johnson & Johnson; Candid Therapeutics, being acquired by UCB; plus Tango Therapeutics, Merida Biosciences, Marea Therapeutics, Synnovation Therapeutics, Azalea Therapeutics and Syremis Therapeutics. Earlier wins include Sage Therapeutics, Editas Medicine and Constellation Pharmaceuticals.

Team

Third Rock was founded in 2007 by Mark Levin, Kevin Starr and Robert Tepper — former Millennium Pharmaceuticals executives. The partnership has since grown to include partners such as Abbie Celniker, Reid Huber, Cary Pfeffer and Neil Exter.

How to apply for funding

Third Rock does not publish a public pitch-submission portal. Because the firm typically creates companies around science it has already identified, the most realistic entry points are a relationship with the partnership, an introduction through its academic and industry networks, or direct contact via the firm's published details — its Boston headquarters lists (617) 585-2000 and its San Francisco office (415) 766-3600.